Rochester Institute of Technology
Self-Assembling Peptide-Based High-Relaxivity Prostate-Cancer-Targeted MRI Contrast Agents
Abstract
dc:description.abstractMagnetic Resonance Imaging (MRI) is a widely used, highly effective imaging method for diagnosing cancer and guiding treatment. MRI contrast agents enhance image quality, with higher relaxivity (r1) contrast agents providing the best utility. Attaching a cancer-specific-targeting group enhances the image further. Therefore, a high-relaxivity cancer-targeted contrast agent is a highly desirable tool for diagnosis and treatment. Our group previously synthesized a peptide-based MRI contrast agent with the Ala(Gd-DO3A) chelator that targeted the prostate cancer biomarker PSMA using the small-molecule ligand DCL. While this agent displayed nominal relaxivity, it was serendipitously found that the relaxivity of a synthetic intermediate containing Fmoc-protected tryptophan (Trp) increased dramatically. This was hypothesized to occur due to intermolecular self-assembly above a critical aggregation concentration (CAC). The first goal was to expand upon this finding by designing peptide-based MRI contrast agents using the simpler Lys(Gd-DOTA) chelator developed earlier in our lab. Di- and tripeptides were synthesized to test the effect of peptide length, net charge, and relative location and stereochemistry of Fmoc, Trp, and Lys(Gd-DOTA) on self-assembly through measuring r1 at 1.0 Tesla. Self-assembly was found to increase r1 from 3-7 to 13-17 mM-1s-1 in H2O and PBS and 11-13 mM-1s-1 in FBS, with remarkably low CACs in FBS. The second goal was to investigate self-assembly using other motifs, including Cbz-protected Trp, two adjacent Trp residues, and other Fmoc-protected aromatic amino acids. The third goal was to apply these findings to synthesize high-relaxivity cancer-targeted MRI contrast agents. Two prostate-cancer-targeted self-assembling MRI contrast agents containing DCL and a breast-cancer-targeted MRI contrast agent containing the peptide 18-4 were synthesized. This work represents the first example of self-assembly in MRI contrast agents induced by Fmoc and aromatic amino acids, and in the broader scope, the synthetic approach is amenable to a wide variety of self-assembling cancer-targeted MRI contrast agents.
Degree
thesis:*- Name thesis:degree_name
- Chemistry (MS)
- Level thesis:degree_level
- Thesis
- Discipline thesis:degree_discipline
- Chemistry and Materials Science, School of
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- O'Brien, Andrew
- Contributors dc:contributor
-
- Hans Schmitthenner
Subjects
dc:subject × 6Identifiers
dc:identifier.*- Repository record dc:identifier
- https://repository.rit.edu/theses/11665